In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70170 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Xiao-Jian Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Atea Pharmaceuticals, Inc., Boston, MA, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Cytochrome P-450 CYP3A, Glucuronosyltransferase, Midazolam. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Atea Pharmaceuticals, Inc.
Abstract (Originalsprache)
Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of CYP3A4. These results prompted further evaluation in a Phase 1 clinical study in healthy participants who received midazolam (a sensitive CYP3A4 substrate) without and with simultaneous or staggered doses of bemnifosbuvir. A single simultaneous 550 mg bemnifosbuvir dose increased the total plasma exposure of a single 2 mg midazolam dose by 24% via reversible inhibition. Simultaneous coadministration of bemnifosbuvir 550 mg twice daily increased the total plasma exposure to midazolam by 98% as an outcome of reversible/time‐dependent inhibition and induction. Simultaneous coadministration of a single and repeat dose of bemnifosbuvir increased the total plasma exposure to 1‐hydroxymidazolam (primary metabolite of midazolam) by 22% and 27%, respectively. Staggered coadministration generally had a lower effect on plasma exposure to both midazolam and 1‐hydroxymidazolam. Conversely, midazolam had no significant effect on the pharmacokinetics of bemnifosbuvir. Overall, bemnifosbuvir was a weak clinical inhibitor (geometric mean ratio
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Atea Pharmaceuticals, Inc., Boston, MA, USA.
- Altasciences Company, Quebec, Canada.
ORCID-Profile: Xiao-Jian Zhou
Förderung
- Atea Pharmaceuticals, Inc
Zitieren
APA
Zhou, X. J., Vo, A., Morelli, G., Montrond, M., Lynch, S., Pietropaolo, K., Belanger, B., Good, S., Horga, A., Agrawal, N., & Hammond, J. (2026). In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70170
Vancouver
Zhou XJ, Vo A, Morelli G, Montrond M, Lynch S, Pietropaolo K, et al. In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70170
BibTeX
@article{Zhou2026,
author = {Zhou, Xiao-Jian and Vo, Alex and Morelli, Gaetano and Montrond, Maureen and Lynch, Shannan and Pietropaolo, Keith and Belanger, Bruce and Good, Steven and Horga, Arantxa and Agrawal, Nancy and Hammond, Janet},
title = {In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70170}
}
EUVIMED